BIOMAT Database Logo BIOMAT Database Logo

Cyclic nucleotide levels in psoriatic and normal keratomed epidermis. 1979

C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D004817 Epidermis The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Cyclic AMP and cyclic GMP production in normal and psoriatic epidermis.
January 1982, Dermatologica,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
The cyclic AMP system in normal and psoriatic epidermis.
July 1972, The Journal of investigative dermatology,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Cyclic nucleotide metabolism in normal and proliferating epidermis.
January 1974, Advances in cyclic nucleotide research,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
August 1978, The Journal of investigative dermatology,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Diurnal variation in cyclic nucleotide levels in normal and phorbol myristate acetate treated mouse epidermis.
April 1980, The Journal of investigative dermatology,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
The 2', 3'-cyclic AMP 3'-phosphohydrolase in normal and psoriatic epidermis.
February 1979, The British journal of dermatology,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Mitoses in normal and psoriatic epidermis.
March 1978, The British journal of dermatology,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Glycoconjugates in normal and psoriatic epidermis.
June 1984, Cutis,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Cyclic adenosine monophosphate, adenyl cyclase and cyclic nucleotide phosphodiesterase in psoriatic epidermis, with a comment on urinary cAMP.
January 1974, Acta dermato-venereologica,
C L Marcelo, and E A Duell, and M A Stawiski, and T F Anderson, and J J Voorhees
Cell proliferation in normal and psoriatic epidermis.
November 1986, The Journal of investigative dermatology,
Copied contents to your clipboard!